Indication
In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Medicine details
- Medicine name:
- isatuximab (Sarclisa)
- SMC ID:
- SMC2804
- Pharmaceutical company
- Sanofi
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 10 November 2025
- SMC meeting date:
- 07 October 2025
- Patient group submission deadline:
- 04 August 2025